Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
VGLT vs XBI: how they differ
VGLT and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Vanguard Long-Term Treasury Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VGLT and XBI hold 0% of their money in the same securities at the same weight.
| Only in VGLT | Only in XBI |
|---|---|
| JPMorgan Chase & Co 0.62% | MODERNA INC 2.87% |
| Mexico Government International Bond 0.50% | TWIST BIOSCIENCE CORP 1.81% |
| United States Treasury Note/Bond 0.49% | HALOZYME THERAPEUTICS INC 1.47% |
| United States Treasury Note/Bond 0.48% | NATERA INC 1.46% |
| United States Treasury Note/Bond 0.48% | KYMERA THERAPEUTICS INC 1.45% |
| Mexico Government International Bond 0.48% | TRAVERE THERAPEUTICS INC 1.40% |
| United States Treasury Note/Bond 0.44% | ROIVANT SCIENCES LTD 1.39% |
| Province of British Columbia Canada 0.43% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Sep 10, 2026.
| VGLT Vanguard Long-Term Treasury Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | Long-term Treasury | SPDR S&P Biotech |
| Total return, 1 year | −5.4% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −22.9 pts | +46.5 pts |
| Expense ratio | not published | 0.35% |
| Holdings | 1703 | 154 |
VGLT in plain words
VGLT is a bond fund tracking the Long-term Treasury. Over the year to Sep 11, 2026 it returned −5.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. It sat 39.2% below its high of Aug 4, 2020 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VGLT or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, VGLT returned −5.4% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VGLT against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/vglt-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources